Mostra i principali dati dell'item

dc.contributor.authorBanales, Jesus M.
dc.contributor.authorIñarrairaegui, Mercedes
dc.contributor.authorArbelaiz, Ander
dc.contributor.authorMilkiewicz, Piotr
dc.contributor.authorMuntané, Jordi
dc.contributor.authorMuñoz-Bellvis, Luis 
dc.contributor.authorLa Casta, Adelaida
dc.contributor.authorGonzález, Luis M.
dc.contributor.authorArretxe, Enara
dc.contributor.authorAlonso, Cristina
dc.contributor.authorMartinez-Arranz, Ibon
dc.contributor.authorLapitz, Ainhoa
dc.contributor.authorSantos-Laso, Alvaro
dc.contributor.authorAvila, Matias A.
dc.contributor.authorMartínez-Chantar, María L.
dc.contributor.authorBujanda, Luis
dc.contributor.authorGarcía Marín, José Juan 
dc.contributor.authorSangro, Bruno
dc.contributor.authorRodríguez Macías, Rocío Isabel 
dc.date.accessioned2024-01-27T16:16:04Z
dc.date.available2024-01-27T16:16:04Z
dc.date.issued2019
dc.identifier.citationBanales, J. M., Iñarrairaegui, M., Arbelaiz, A., Milkiewicz, P., Muntané, J., Muñoz‐Bellvis, L., ... & Macias, R. I. (2019). Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology, 70(2), 547-562. DOI: 10.1002/hep.30319es_ES
dc.identifier.issn0270-9139
dc.identifier.urihttp://hdl.handle.net/10366/154809
dc.description.abstract[EN]Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods represents a current clinical challenge. The analysis of low-molecular-weight metabolites by new high-throughput techniques is a strategy for identifying biomarkers. Here, we have investigated whether serum metabolome can provide useful biomarkers in the diagnosis of iCCA and HCC and could discriminate iCCA from HCC. Because primary sclerosing cholangitis (PSC) is a risk factor for CCA, serum metabolic profiles of PSC and CCA have also been compared. The analysis of the levels of lipids and amino acids in the serum of patients with iCCA, HCC, and PSC and healthy individuals (n = 20/group) showed differential profiles. Several metabolites presented high diagnostic value for iCCA versus control, HCC versus control, and PSC versus control, with areas under the receiver operating characteristic curve (AUC) greater than those found in serum for the nonspecific tumor markers carbohydrate antigen 19-9 (CA 19-9) and alpha-fetoprotein (AFP), commonly used to help in the diagnosis of iCCA and HCC, respectively. The development of an algorithm combining glycine, aspartic acid, SM(42:3), and SM(43:2) permitted to accurately differentiate in the diagnosis of both types of tumors (biopsy-proven). The proposed model yielded 0.890 AUC, 75% sensitivity, and 90% specificity. Another algorithm by combination of PC(34:3) and histidine accurately permitted to differentiate PSC from iCCA, with an AUC of 0.990, 100% sensitivity, and 70% specificity. These results were validated in independent cohorts of 14-15 patients per group and compared with profiles found in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Conclusion: Specific changes in serum concentrations of certain metabolites are useful to differentiate iCCA from HCC or PSC, and could help in the early diagnosis of these diseases.es_ES
dc.description.sponsorshipSupported by CIBERehd (EHD15PI05), AECC Scientific Foundation (2017/2020), “Fondo de Investigaciones Sanitarias” (Carlos III Health Institute: PI15/01132 and PI18/01075 to J.M.B., PI16/00598 to J.J.G.M., PI16/01845 to B.S., PI16/01126 to M.A.A., PI16/00090 to J.M.), Spanish Ministry of Economy, Industry and Competitiveness (SAF2016‐75197‐R to R.I.R.M., SAF2017‐87301‐R to M.L.M.‐C.), Miguel Servet Programme (CON14/00129 to J.M.B.), “Diputación Foral de Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), “Basque Foundation for Innovation and Health Research: EiTB Maratoia” (BIO15/CA/016/BD to J.M.B., BIO15/CA/016/BD to M.L.M.‐C.), Basque Country Department of Health (2013111173 to L.B., 2017111010 to J.M.B., 2013111114 to M.L.M.‐C.), the Andalusian Government (“Consejería de Economía, Innovación, Ciencia y Empleo”: CTS‐6264 and “Consejería de Salud”: PI‐0198‐2016 to J.M.), Junta de Castilla y León, Spain (SA063P17 to J.J.G.M.), European Comission Horizon 2020 project (SEP‐210503876; ESCALON to J.M.B.), and Proyecto Hepacare, Fundación La Caixa (to M.A.A.).es_ES
dc.language.isoenges_ES
dc.publisherLippincott, Williams & Wilkinses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectSerum Metaboliteses_ES
dc.subjectDiagnostic Biomarkerses_ES
dc.subjectCholangiocarcinomaes_ES
dc.subjectHepatocellular Carcinomaes_ES
dc.subjectPrimary sclerosing cholangitises_ES
dc.subject.meshCholangiocarcinoma *
dc.subject.meshCarcinoma, Hepatocellular *
dc.titleSerum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionDOI: 10.1002/hep.30319es_ES
dc.subject.unesco3213.01 Cirugía Abdominales_ES
dc.identifier.doi10.1002/hep.30319
dc.relation.projectID“Fondo de Investigaciones Sanitarias” (Carlos III Health Institute: PI15/01132 and PI18/01075 to J.M.B., PI16/00598 to J.J.G.M., PI16/01845 to B.S., PI16/01126 to M.A.A., PI16/00090 to J.M.), Spanish Ministry of Economy, Industry and Competitiveness (SAF2016‐75197‐R to R.I.R.M., SAF2017‐87301‐R to M.L.M.‐C.), Miguel Servet Programme (CON14/00129 to J.M.B.), “Diputación Foral de Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), “Basque Foundation for Innovation and Health Research: EiTB Maratoia” (BIO15/CA/016/BD to J.M.B., BIO15/CA/016/BD to M.L.M.‐C.), Basque Country Department of Health (2013111173 to L.B., 2017111010 to J.M.B., 2013111114 to M.L.M.‐C.), the Andalusian Government (“Consejería de Economía, Innovación, Ciencia y Empleo”: CTS‐6264 and “Consejería de Salud”: PI‐0198‐2016 to J.M.), Junta de Castilla y León, Spain (SA063P17 to J.J.G.M.), European Comission Horizon 2020 project (SEP‐210503876; ESCALON to J.M.B.), and Proyecto Hepacare, Fundación La Caixa (to M.A.A.).es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1527-3350
dc.journal.titleHepatologyes_ES
dc.volume.number70es_ES
dc.issue.number2es_ES
dc.page.initial547es_ES
dc.page.final562es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decscolangiocarcinoma *
dc.subject.decscarcinoma hepatocelular *


Files in questo item

Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional